`
`
`
`1001
`1002
`
`U.S. PatentNo. 8,791,154 B2 (“”154 Paten ”)
`U.S. PatentNo. 9,533,053 B2 (“’053 Patent”)
`
`1003 WO 2008/015695 A2 (“Bhowmick”)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`1004
`YANNI et a[., “The In Vitro and In Vivo Ocular Pharmacology of
`
`
`Olopatadine (AL—4943A), an Effective Anti-Allergic/Antihistaminic
`
`
`Agen ,” Journal of Ocular Pharmacology and Therapeutics, Volume
`
`
`12, Number 4, 1996, pp. 389-400 (“Yanni”)
`
`
`
`
`1005
`U.S. Pat. No. 6,995,186 B2 (“Castillo”)
`
`U.S. Pat. Pub. No. 201 1/0082145 A1 (“Schneider”)
`
`U.S. Pat. No. 5,641,805 (“Hayakawa”)
`
`File Wrapper forU.S. PatentNo. 8,791,154 B2
`
`
`File Wrapper for U. S. Provisional Appl. No. 61/487,789
`
`
`File Wrapper for U. S. Provisional Appl. No. 61/548,957
`
`
`Physician’s Desk Reference - PATANOL®; PATADAY® (“PDR”)
`
`Handbook ofP harmaceutical Excipients
`
`
`
`David B. Troy, Remington: The Science andPractz'ce ofPharmacy,
`
`
`
`Philadelphia College of Pharmacy and Science 21 st Ed, 229, 856—866
`1013
`
`
`(2005)
`
`
`1014 Declaration of Dr. Laskar
`
`
`
`
`
`
`
`1006
`
`1007
`
`1008
`
`1015
`
`1016
`
`1017
`
`
`
`Argentum Pharm. LLC v. Alcon Research, Ltd, IPR2016—00544,
`
`Paper 8 (PTAB July 18, 2016)
`
`
`
`Apotex, Inc. v. Alcon Research Ltd, IPR2016-01640, Paper 2 G’TAB
`Aug. 18, 2016)
` Alcon Research, Ltd v. Watson Labs, l-15—cv-01159 (D. Del.) Paper
`
`69 (November 18, 2016)
`
`
`
`
`
`Argentum Pharm. LLC v. Alcon Research Ltd,
`Paper 1 (PTAB Feb. 2, 2016)
`
`lPR2016—00544,
`
`U.S. PatentNo. 6,770,675
`
`
`
`Abelson & Gomes, “Olopatadine 0.2% ophthalmic solution: the first
`ophthalmic
`antiallergy agent with once—daily dosing,” Expert
`
`
`Opinion on Drug Metabolism & Toxicology, 4:4, 453—461 (2008)
`
`
`
`Pharmaceutical Calculations, 13th Ed., Ansell, 2010
`
`
`
`
`
`
`Apotex, Inc. v. Alcon Research Ltd, IPR2016—01640, Paper 3 (PTAB
`Aug. 18, 2016)
`
`
`
`Apotex, Inc. v. Alcon Research Ltd , lPR2016—01640, Paper 8 (PTAB
`Oct. 5, 2016)
`
`Apotex, Inc. V. Alcon Research Ltd, IPR2016-01640, Paper 9 (PTAB
`Nov. 30, 2016)
`
`
`
`
`Abelson & Loeffler, Conjunctival Allergen Challenge: Models in the
`Investigation of Ocular Allergy, Current Allergy and Asthma Reports
`3:363—368 (2003)
`
`
`Eiichi Uchio, Treatment of allergic conjunctivitis with olopatadine
`hydrochloride eye drops, Clinical Ophthalmology 2(3):525—53 1, 527-
`
`528 (2008)
`
`
`
`0.2%
`“Efiicacy of Once—Daily Olopatadine
`al.,
`Abelson et
`Ophthalmic Solution Compared to Twice-Daily Olopatadine 0.1%
`
`
`Ophthalmic Solution for the Treatment of Ocular Itching Induced by
`
`
`Conjunctival Allergen Challenge,” Current Eye Research 32:1017—
`
`
`1022 (2007)
`
`
`
`
`
`
`
`Leonardi, et al., “The anti-allergic effects of a cromolyn sodium—
`chlorpheniramz'ne
`combination compared to
`ketotz'fen
`in
`the
`conjunctival
`allergen
`challenge model,”
`European
`J.
`of
`Ophthalmology 13(2):128-133 (2003)
`
`1029 US. Patent PublicationNo. 2008/0085922
`
`1030
`
`Alcon Research, Ltd v. Watson Labs. ,
`155 (March 1, 2018)
`
`l-lS—CV—Ol 159 (D. Del.) Paper
`
`1031
`
`https://Www.pazeodrops.com/
`
`
`
`Nandi et al., “NANDI et al., “Synergistic Effect of PEG-400 and
`Cyclodextrin to Enhance Solubility of Progesterone,” AAPS
`PharmSciTech 2003; 4 (1), pp 1-5.”
`
`1037
`
`CV of Dr. Paul Laskar
`
`1038
`
`Handbook of Chemistry and Physics 2006, 87th Ed.
`
`1039 US. Publication No. 2004/0198828 (“Abelson”)
`
`1040
`
`
`
`Ophthamologica Scandinavica, 2002, pp. 144-150.
`
`in eye drop fonnulations:
`“Cyclodextrins
`LOFTSSON et al.,
`enhanced topical delivery of corticosteroids to the eye,” Acta
`
`